Oncolytics Biotech® Announces Investigator Sponsored Multiple Myeloma Study Combining REOLYSIN® and Nivolumab (Opdivo®) with Standard of Care

CALGARY, Alberta and SAN DIEGO, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (ONC.TO) (ONCY), currently developing REOLYSIN ® (pelareorep), an intravenously delivered immuno ...

EMA committee recommends approval of Bristol-Myers Squibb's Opdivo four-week dosing schedule for advanced melanoma & previously treated RCC

Bristol-Myers Squibb Company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval of an every four-week (Q4W) Opdivo (nivo...